ME
Mesoblast Limited
MEOBF · OTC
$1.90 +0.00% (+$0.00)
1M +0.53%
Market Cap $2.46B
P/E Ratio -
Div. Yield -
ROE 10.14%
Piotroski F-Score Moderate
4/9Valuation
23 /100
Expensive P/S 20.07x
P/B 4.34x
P/E N/A
Growth
88 /100
Growing Rev. growth 153.89%
Book val. growth 4.24%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 84.09%
Net margin 47.82%
FCF margin 36.43%
Quality
2 /100
Poor ROIC 7.50%
ROE 10.14%
Asset turnover 0.16x
Debt
69 /100
Low Debt/Equity 0.22x
Current ratio 2.43x
Int. coverage -2.15x
Stability
49 /100
Moderate Beta 0.81x
Rev. volatility 323.29%
Profitable years 0
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o MEOBF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Silviu Itescu
Employees
108
Headquarters
Melbourne
Nadchodzące wydarzenia
04 MAR
Earnings
Upcoming earnings report